StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
KLRSKalaris Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$1.88▼ 0.53%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $44.7MShares out 23.8M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

6
  • 8.28After-hours26.08.29 05:10
    4Ownership#●●●

    Kalaris Therapeutics, Inc.

    Insider Amy O'Leary Vandekop of Kalaris Therapeutics filed a Form 4 on August 28, 2026, reporting a change in beneficial ownership of securities as of August 27, 2026. This filing officially documents the insider's equity transaction to ensure transparency for shareholders.…more

    $1.88-0.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.11After-hours26.08.12 05:00
    10-QEarnings

    Kalaris Therapeutics, Inc.

    Kalaris Therapeutics(KLRS)가 2026년 6월 30일로 종료된 분기에 대한 10-Q 분기 보고서를 제출했습니다. 본 공시는 경영진의 재무 보고 및 내부 통제에 대한 인증을 포함하고 있으며, 회사의 재무 상태와 운영 결과를 공식적으로 보고합니다.…more

    $1.88-0.53%vs prev close
    View filingShare
  • 8.11Pre-market26.08.11 21:05
    8-KKey event

    Kalaris Therapeutics, Inc.

    칼라리스 테라퓨틱스는 2026년 2분기 1,150만 달러의 순손실을 기록했으며, 6월 30일 기준 9,350만 달러의 현금 및 유가증권을 보유하고 있습니다. 현재 주력 파이프라인인 TH103의 임상 1b/2상 투약이 진행 중이며, 2027년 상반기에 예비 데이터를 발표할 예정입니다.…more

    $1.88-0.53%vs prev close
    View filingShare

5 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.31Pre-market26.08.31 21:00
    #●●●#●●●

    Kalaris Therapeutics to Present at Morgan Stanley Global Healthcare Conference…more

    Kalaris Therapeutics announced that its management will participate in a fireside chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. The session will provide an opportunity to discuss the clinical progress of its retinal disease therapeutic candidate, TH103.…more

    $1.88-0.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.11Pre-market26.08.11 21:00

    ●●●●●●●● ●●●●● ●●●●●●

    칼라리스는 망막 질환 치료제 후보물질 TH103의 임상 1b/2상 환자 투약을 순조롭게 진행 중이며 2027년 상반기 예비 데이터를 발표할 예정이다. 현재 보유 현금은 2027년 4분기까지의 운영 자금으로 충분하여 주요 임상 마일스톤 달성까지 안정적인 재무 상태를 유지하고 있다.…more

    $1.88-0.53%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →